SUS Barra Inclusion of Ozepic, Wegovy and Saxenda

Pens are imported and have a high cost. They are from the New Danish Laboratory Nordisk and are marketed by pharmacies from R $ 963, depending on the medicine, dose and where it is purchased (e-commerce or physical store) and may reach R $ 1,799.

According to a report by the Ministry of Health, the cost of drugs would be R $ 6.4 billion (semaglutado) and R $ 9.8 billion (liraglutide) in five years. This was the main argument for not incorporating them into the public health system.

Pharmaceuticals said in a note understanding that “challenges” prevent the offer of innovative technologies. “Novo Nordisk understands that SUS’s historic subfinance, added to the context of fiscal imbalance, budget restrictions and obsolescence of current incorporation mechanisms today, impose challenges for the provision of health technologies to the national population, even when they are evidently cost-effective.” The laboratory also said it reaffirmed its commitment to the confrontation of obesity in Brazil.

Ems launched a slimming pen in early August. Olire is a liraglutide -based medicine, as well as Saxenda and Victoza, and is the first done by a Brazilian pharmacist. Prices are still high, but are below the value of competitors: ranges from $ 307 to $ 760. The Ministry of Health announced two weeks ago that it will produce its own pens in partnership with EMS itself and Fiocruz.

SUS offers alternatives against obesity. Currently, the public system provides approaches such as food orientation, incentive to physical activity and psychological support, as well as bariatric surgery in specific cases.

Pens are approved for use in Brazil. Since June, it is mandatory to present medical prescription in pharmacies to buy the so -called weight loss pens – a route of revenue is retained. Anvisa’s decision came after the popularization of this type of medicine on social networks and the use for purely aesthetic weight loss and without proper medical follow -up.